Moderna is trading 4.23% down at $190.47 in pre-market on September 28; weaker global risk sentiment may be contributing, but no clear new company-specific announcement explaining the move surfaced in available search results. - Shares closed at $198.88 on September 25. - President Trump rejected Iran’s proposal on the Strait of Hormuz, lifting oil prices and weighing on global markets. - U.S. futures also declined; available evidence does not establish a direct cause for Moderna’s drop.